TD Cowen analyst Brendan Smith has maintained their bullish stance on RPID stock, giving a Buy rating on August 13.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brendan Smith has given his Buy rating due to a combination of factors that indicate a promising future for Rapid Micro Biosystems. The company’s consistent order commitments from Millipore Sigma and the durable revenue from services and consumables are seen as strong advantages. Additionally, the onshoring of manufacturing in the US, with a focus on automation, is expected to provide significant growth opportunities through fiscal year 2026.
Smith also highlights the company’s robust sales funnel, which includes multiple system rollouts and purchase commitments from MilliporeSigma starting in fiscal year 2026. The growth of the installed base is expected to drive consumables and service revenue, while the company’s competitive positioning is well-suited to benefit from the shift towards automation in biopharma manufacturing. Despite some uncertainties in spending and tariffs, the potential for cost savings through automation, particularly with the Growth Direct system, is seen as a compelling incentive for biopharma customers, supporting the Buy rating.
In another report released on August 13, Lake Street also maintained a Buy rating on the stock with a $8.00 price target.